HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
YvX248e21g3f3E84